GSK3B and cancer: Some studies have shown that overexpression of CDC25A in cancers could result from post-transcriptional deregulations [20] such as overexpression of DUB3 ubiquitin hydrolase [21], inactivation of glycogen synthase kinase-3beta (GSK-3beta), which phosphorylates CDC25A to promote its proteolysis in early cell-cycle phases [22], activation of LIN28A that regulates CDC25A expression by inhibiting the biogenesis of let-7 miRNA [23], and microRNA-21 which negatively regulates CDC25A, so that its under-expression results in CDC25A overexpression in colon cancer [24].